Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Alli

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
DNA Repair|March 20, 2012
Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomolElizabeth Alli, James M Ford
DNA Repair|May 10, 2015
BRCA1: Beyond double-strand break repairElizabeth Alli, James M Ford
Molecular & Cellular Oncology|June 17, 2016
BRCA1: a movement toward cancer preventionElizabeth Alli, James M Ford
Cancer Research|August 28, 2010
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatinKedar Hastak, Elizabeth Alli, James M Ford
Cancer Research|April 9, 2009
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymeraseElizabeth Alli, Vandana B Sharma, Preethi Sunderesakumar, et al.
Cancer Research|December 4, 2002
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancerElizabeth Alli, Judy Bash-Babula, Jin-Ming Yang, et al.
Cancer Research|September 14, 2014
Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repairElizabeth Alli, David Solow-Cordero, Stephanie C Casey, et al.
Molecular Pharmacology|February 3, 2007
Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cellsElizabeth Alli, Jin-Ming Yang, James M Ford, et al.
BMC Pharmacology|July 21, 2011
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cellsElizabeth Alli, Vandana B Sharma, Anne-Renee Hartman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4Judy Bash-Babula, Deborah Toppmeyer, Marie Labassi, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
DNA Repair|March 20, 2012
Breast cancers with compromised DNA repair exhibit selective sensitivity to elesclomolElizabeth Alli, James M Ford
DNA Repair|May 10, 2015
BRCA1: Beyond double-strand break repairElizabeth Alli, James M Ford
Molecular & Cellular Oncology|June 17, 2016
BRCA1: a movement toward cancer preventionElizabeth Alli, James M Ford
Cancer Research|August 28, 2010
Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatinKedar Hastak, Elizabeth Alli, James M Ford
Cancer Research|April 9, 2009
Defective repair of oxidative dna damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymeraseElizabeth Alli, Vandana B Sharma, Preethi Sunderesakumar, et al.
Cancer Research|December 4, 2002
Effect of stathmin on the sensitivity to antimicrotubule drugs in human breast cancerElizabeth Alli, Judy Bash-Babula, Jin-Ming Yang, et al.
Cancer Research|September 14, 2014
Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repairElizabeth Alli, David Solow-Cordero, Stephanie C Casey, et al.
Molecular Pharmacology|February 3, 2007
Reversal of stathmin-mediated resistance to paclitaxel and vinblastine in human breast carcinoma cellsElizabeth Alli, Jin-Ming Yang, James M Ford, et al.
BMC Pharmacology|July 21, 2011
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cellsElizabeth Alli, Vandana B Sharma, Anne-Renee Hartman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 15, 2002
A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4Judy Bash-Babula, Deborah Toppmeyer, Marie Labassi, et al.
Pageof 2